Fulcrum Therapeutics: Funding, Investors & Team (Sep 2026)
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.
Fulcrum Therapeutics has raised $375M across 3 funding rounds on record, the most recent an undisclosed round of $175M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Fulcrum Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Fulcrum Therapeutics Funding Rounds
Fulcrum Therapeutics raised $125M in a Post-IPO Equity announced in Aug 2021.
1 years later, a Post-IPO Equity of $75.0M was announced in Aug 2022.
3.3 years later, an undisclosed round of $175M was announced in Dec 2025.
Fulcrum Therapeutics Founders and Leadership Team
Contact details for the Fulcrum Therapeutics team: 1 of 3 have an email address on file.
Start 14-day free trial →Fulcrum Therapeutics Funding Compared to Other Biotechnology Startups
Fulcrum Therapeutics' latest round of $175M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Fulcrum Therapeutics in Biotechnology and Cambridge
Companies Similar to Fulcrum Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Fulcrum Therapeutics Funding FAQs
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.
How much funding has Fulcrum Therapeutics raised?
Fulcrum Therapeutics has raised $375M across 3 rounds on record. The most recent is an undisclosed round of $175M announced in Dec 2025.
When did Fulcrum Therapeutics last raise funding?
Fulcrum Therapeutics' most recent funding round on record is an undisclosed round of $175M, announced in Dec 2025.
Who founded Fulcrum Therapeutics?
FundedIQ lists Rudolf Jaenisch (Founder) at Fulcrum Therapeutics.
Who is the CEO of Fulcrum Therapeutics?
Bryan Stuart is listed as CEO at Fulcrum Therapeutics.
Where is Fulcrum Therapeutics headquartered?
Fulcrum Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Fulcrum Therapeutics have?
Fulcrum Therapeutics is in the 101-250 employee band.
How does Fulcrum Therapeutics' funding compare to other Biotechnology startups?
Fulcrum Therapeutics' latest round of $175M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Fulcrum Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Fulcrum Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.